Table 6.
PS‐Adjusted ORs (After Bonferroni Correction) for Each of the Considered Outcomes in the CoreValve Subgroup for the Sensitivity Analysis
| Outcome | OR (95% CI) Before and During TAVI BAV | OR (95% CI) Before and No During TAVI BAV | OR (95% CI) No Before and During TAVI BAV |
|---|---|---|---|
| 30‐day mortality | 1.71 (0.46, 6.42) | 0.84 (0.06, 12.13) | 0.86 (0.33, 2.26) |
| MI | NA | NA | 2.91 (0.06, 137.8) |
| Stroke | 0.48 (0.05, 5.09) | NA | 0.96 (0.28, 3.30) |
| Moderate/severe AR/PVL | 1.90 (0.77, 4.65) | 0.68 (0.12, 4.00) | 1.13 (0.58, 2.17) |
| CAO | 0.40 (0.01, 22.63) | NA | 0.46 (0.06, 3.78) |
| Valve dysfunction | 0.60 (0.14, 2.62) | 0.64 (0.04, 9.23) | 0.55 (0.21, 1.44) |
| Pacemaker implantation | 1.14 (0.45, 2.86) | 0.80 (0.18, 3.63) | 1.26 (0.71, 2.23) |
| Device migration | 1.21 (0.15, 10.03) | 1.34 (0.12, 15.03) | 0.89 (0.26, 3.06) |
| Hemofiltration/dialysis | 0.84 (0.13, 5.51) | 0.37 (0.01, 14.33) | 0.88 (0.31, 2.53) |
| MVC | 0.75 (0.14, 4.00) | 1.43 (0.15, 13.91) | 0.74 (0.27, 2.07) |
| Early safety | 0.98 (0.47, 2.05) | 0.69 (0.18, 2.61) | 0.82 (0.51, 1.34) |
Note that the direct‐TAVI group was taken as the reference. AR indicates aortic regurgitation; BAV, balloon aortic valvuloplasty; CAO, coronary artery obstruction; MI, myocardial infarction; MVC, major vascular complication; NA, not applicable; ORs, odds ratios; PS, propensity score; PVL, paravalvular leakage TAVI, transcatheter aortic valve implantation.